Table 2.
Clinical trials of sunitinib
| Patients | Phase | Treatment | n | OS (m) | PFS (m) | TTP (m) | RR | DCR |
| Pretreated patients with advanced gastric cancer | II | Sunitinib | 51 | 5.8 | 1.28 | N/A | 3.9% | 20.0% |
| Second line treatment for advanced gastric cancer | II | Sunitinib | 78 | 6.8 | 2.3 | 2.3 | 2.6% | 34.7% |
| Unresectable or metastatic advanced gastric cancer after failed treatment with fluoropyrimidine + platinum | II | Docetaxel | 49 | 6.6 | N/A | 2.6 | 14.3% | 51.0% |
| Docetaxel + sunitinib | 56 | 8.0 | N/A | 3.9 | 41.1% | 75.0% |
DCR: Disease control rate; N/A: Not available; OS: Overall survival; PFS: Progression-free-survival; RR: Response rate; TTP: Time to progression.